Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) corresponding to the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro stabiliser, molecular weight ≈ 911 Da, marketed in South Africa strictly as a research peptide and referenced in the literature for putative BDNF and neurotrophic signalling effects. For 2026 researchers looking to buy Semax peptide in South Africa, local supply concentrates among research-chemical vendors such as Reschem (listed at R599.00 for a generic Semax SKU) and JCSG.org's Body Pharm Semax 10 line, with no SAHPRA scheduling notice naming ACTH-fragment heptapeptides located in open registers as of 2025–2026. This guide consolidates the ACTH(4-7)-Pro-Gly-Pro scaffold biochemistry, the 2024–2026 BDNF evidence gap flagged by Biomeme and ADDF, and transparent ZAR sourcing context for South African labs. Last updated: 12 February 2026.

Key Takeaways

• Semax is an unscheduled research peptide in South Africa; no SAHPRA registration or human-use authorisation exists as of 2026
• BDNF upregulation evidence is preclinical only, with no PubMed-indexed human trials published since 2023
• Local supply ranges from R599 to R900 per 10 mg vial; verify batch-specific Certificates of Analysis before purchase
• Intranasal administration at 50–100 µg/kg is the standard rodent research route; no human dosing protocol is endorsed
• Semax and Selank are structurally similar but mechanistically distinct; endpoint-driven selection is essential

What Is Semax? Structure and Origin Explained

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to residues 4–7 of adrenocorticotropic hormone (ACTH(4-7)) extended at the C-terminus with a Pro-Gly-Pro tripeptide stabiliser. The Institute of Molecular Genetics of the Russian Academy of Sciences developed it in the 1980s as a non-hormonal ACTH analogue. Its molecular formula is C₃₇H₅₁N₉O₁₀S and its average molecular mass is approximately 813 Da for the free peptide base, calculated by summing the residue masses with loss of water at each peptide bond.

Why the Pro-Gly-Pro extension matters

The parent ACTH(4-7) tetrapeptide (Met-Glu-His-Phe) undergoes rapid cleavage by serum and brain aminopeptidases, giving it a plasma half-life of minutes and limiting any sustained central nervous system signal. Appending Pro-Gly-Pro at the C-terminus sterically blocks carboxypeptidase access and substantially extends the functional half-life. That stabilisation strategy is the engineering rationale behind Semax as a research tool rather than the native ACTH fragment. The same logic was later applied to Selank, the anxiolytic tuftsin analogue developed by the same Russian group, which also carries a Pro-Gly-Pro tail.

Distinguishing Semax from related research peptides

Semax differs from ACTH(4-10), α-MSH, and the bare ACTH(4-7) tetrapeptide. The seven-residue Pro-Gly-Pro-extended form is the specific entity referenced in the Dolotov et al. (2006) neurotrophic and BDNF-adjacent transcriptomic literature. Researchers cross-comparing neuropeptide scaffolds for in vitro neuronal work often shortlist Semax alongside Epithalon (Ala-Glu-Asp-Gly) and Selank, though their target pathways diverge sharply once past the shared "short synthetic regulatory peptide" classification.

Semax and BDNF: What the Research Shows (2024 Update)

Semax upregulates BDNF (brain-derived neurotrophic factor) mRNA in rodent hippocampus and cortex. As of 2026, the strongest causal evidence remains preclinical and predates 2023, with no PubMed-indexed BDNF-quantification study on Semax published in the 2023–2026 window. BDNF is a neurotrophin, a protein that binds the TrkB receptor to drive synaptic plasticity, long-term potentiation, and neuronal survival, which is why any compound that elevates BDNF transcription attracts neuroscience research interest.

Researchers concerned about the translational gap between rodent models and human application should note that no Western-standard randomised controlled trial has yet quantified BDNF changes in human subjects receiving Semax.

Preclinical BDNF and neurotrophic findings

Dolotov et al. (2006) first reported that a single intranasal dose of Semax increases BDNF and TrkB mRNA in rat hippocampus within hours of administration. Dose ranges in rodent models are typically cited at 50–150 µg/kg intranasal. Follow-up transcriptomic work by Medvedeva and colleagues, summarised in a 2014 PMC paper on ischaemia-reperfusion, showed Semax modulating expression of genes linked to immune signalling, vascular response, and neurotrophin pathways in rat cortex after middle cerebral artery occlusion. Agapova et al. (2007) ischaemia models reported neuroprotective effects at comparable intranasal doses. These data are now nearly two decades old and have not been replicated under modern reporting standards.

State of the 2023–2026 evidence

The most recent mechanistic English-language paper of note is Giuliani et al. (2021), which showed Semax binds Cu²⁺ and inhibits Aβ:Cu²⁺ fibrillogenesis in neuronal models, without directly quantifying BDNF. As of 2026, no Cochrane-style or PRISMA-compliant systematic review of Semax's cognitive or neuroprotective effects has been indexed. The 2024 Biomeme evidence profile explicitly flags the absence of Western-standard randomised trials. Human clinical data remains limited to Russian-language stroke and cognitive-impairment reports that have not been translated into pooled effect sizes.

What this means for the SA researcher

All BDNF-related claims for Semax derive from animal or in-vitro models unless explicitly sourced to a human trial. Any 2026 protocol design should treat the 50–100 µg/kg intranasal rodent range as the reference point, not an extrapolation to humans. Researchers cross-comparing neuropeptide mechanisms should review the Selank research peptide literature for a Pro-Gly-Pro-stabilised parallel, and the Epithalon peptide record for a structurally unrelated longevity-focused comparator.

Semax vs Selank: Key Differences for Researchers

Semax and Selank are both Pro-Gly-Pro-stabilised synthetic heptapeptides developed at the Russian Academy of Sciences, but they derive from different parent molecules and address different research endpoints. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analogue investigated for cognitive and neurotrophic effects; Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a tuftsin analogue investigated primarily for anxiolytic and immunomodulatory effects. They are not interchangeable.

The shared C-terminal Pro-Gly-Pro tripeptide confers enzymatic stability against aminopeptidases, which is why both compounds remain active after intranasal administration. The N-terminal pharmacophore is where they diverge mechanistically. Semax's Met-Glu-His-Phe segment corresponds to residues 4–7 of adrenocorticotropic hormone and engages melanocortin-related and neurotrophin pathways. Andreeva-era transcriptomic data shows modulation of BDNF and TrkB transcripts in ischaemic rat cortex. Selank's Thr-Lys-Pro-Arg segment is tuftsin-derived and the literature concentrates on GABAergic and enkephalinase-related anxiolytic endpoints rather than direct BDNF quantification.

Side-by-side comparison

Parameter	Semax	Selank
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Parent peptide	ACTH(4-7)	Tuftsin (TKPR)
Molecular weight	≈911 Da	≈751 Da
Primary reported mechanism	BDNF/NGF expression, melanocortin signalling	Enkephalinase inhibition, GABAergic tone
Dominant research endpoint	Cognitive, neuroprotective (ischaemia models)	Anxiolytic, immunomodulatory
Typical study route	Intranasal 50–100 µg/kg (rodent)	Intranasal

For SA researchers selecting between the two, the decision is endpoint-driven. Protocols probing neurotrophin signalling, cortical gene expression, or post-ischaemic recovery point to Semax; protocols probing anxiety models, stress reactivity, or cytokine profiles point to the Selank research peptide. Investigators building a wider neuropeptide comparison set may also reference the Epithalon peptide literature, though Epithalon's tetrapeptide structure and telomerase-focused mechanism place it in a separate class entirely.

Semax as a Nootropic Research Compound: Cognitive Endpoints

In a research context, "nootropic" denotes a compound investigated for measurable effects on learning, memory consolidation, or attention in controlled behavioural assays, not a registered cognitive-enhancer indication. No South African regulator, nor the FDA or EMA, has approved Semax for any cognitive endpoint in humans.

Rodent behavioural endpoints

The bulk of cognitive data derives from rat models using the Morris water maze (spatial learning and reference memory) and passive avoidance paradigms (associative memory consolidation). Andreeva and colleagues' transcriptomic series in ischaemic rat cortex linked intranasal Semax at 50–100 µg/kg to altered expression of neurotrophin- and vascular-pathway genes, with downstream behavioural recovery used as a functional readout. Mechanistic reviews extending that work describe attention- and memory-related improvements in normotypic and lesioned rats. The primary experimental papers cited in those reviews predate 2020 and should be treated as methodologically stale for a 2026 evidence base.

Human data and its limitations

Human Semax data is dominated by Russian-language clinical reports on ischaemic stroke, optic neuropathy, and cognitive impairment, most published before 2010 and not indexed to current PRISMA standards. No PubMed-indexed 2024–2026 systematic review or meta-analysis has pooled cognitive endpoints into quantitative effect sizes. Contemporary English-language profiles, including the 2024 Biomeme evidence score and the 2026 Innerbody overview, classify Semax as a research peptide with promising but unconsolidated cognitive signals.

Researchers seeking human-trial data should be aware that the absence of recent English-language publications does not confirm efficacy or safety in human populations.

Disclaimer

This page is a research-context overview only. Nothing here constitutes medical advice, a therapeutic claim, or a recommendation for human administration. SA researchers comparing mechanism-matched neuropeptides may also consult the Selank research peptide literature for anxiolytic endpoints, and the Epithalon peptide record for longevity-adjacent neuroscience work.

Body Pharm Semax 10: Product Specifications

Body Pharm Semax 10 is a 10 mg lyophilised peptide vial of the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH(4-7)-Pro-Gly-Pro, MW ≈ 911 Da), supplied for in vitro and preclinical research use only and not for human therapeutic administration. No 2024–2026 Body Pharm technical sheet or JCSG.org listing with an explicit HPLC purity percentage or downloadable Certificate of Analysis was located in open sources at the time of writing on 12 February 2026. The specifications below combine vendor-typical conventions with what SA buyers should verify directly before purchase.

Vial and purity

The standard format is a single 10 mg vial of white-to-off-white lyophilised powder under inert headspace. High-end research-peptide suppliers typically certify ≥98% HPLC purity by reversed-phase HPLC for neuropeptides of this class. Body Pharm's exact specification for the Semax 10 SKU should be confirmed via a batch-specific COA requested from the distributor.

Buyers concerned about batch variability should request the HPLC chromatogram and mass-spectrometry data before committing to a large order.

Storage and reconstitution

Store the sealed vial at −20 °C, protected from light and moisture. Lyophilised Semax is generally stable for 24+ months under those conditions. For research reconstitution, bacteriostatic water (0.9% benzyl alcohol) is the conventional diluent, with aliquoting recommended to avoid freeze-thaw cycles on the working stock. Cold-chain shipping with insulated packaging and gel packs is the expected dispatch standard for the lyophilised vial in transit to SA labs.

Price and sourcing in ZAR

As a 2026 local benchmark, Reschem lists a comparable lyophilised Semax research peptide at R599.00 per vial. Body Pharm Semax 10 pricing through SA distributors typically falls in the R600–R900 range per 10 mg vial, subject to batch and exchange rate. Confirm the live ZAR figure on the supplier's current catalogue before ordering.

Researchers cross-comparing neuropeptide scaffolds may also review the Selank research peptide profile (the closest structural analogue) and the Epithalon peptide record for adjacent neuroscience endpoints.

Sourcing Semax in South Africa: What Researchers Should Know in 2026

Semax is sold in South Africa as an unscheduled research chemical, not as a registered medicine. No SAHPRA scheduling notice, registration decision, or guideline explicitly naming Semax or the ACTH(4-7)-Pro-Gly-Pro scaffold was located in open 2025–2026 records. International regulatory commentary confirms it has not been evaluated by Western agencies such as the FDA. Under the Medicines and Related Substances Act 101 of 1965, any human administration would require regulatory authorisation that has not been granted for this compound. SA vendors therefore market it strictly for in vitro and preclinical research.

What legitimate supply looks like

A credible SA research-peptide supply chain includes:

• A batch-specific Certificate of Analysis matching the lot on the vial label
• Reversed-phase HPLC purity data, typically ≥98% for neuropeptides of this class
• Mass-spectrometry confirmation of the ≈911 Da heptapeptide
• Cold-chain shipping with insulated packaging and temperature-monitored dispatch
• A South African dispatch address and a published returns or batch-failure policy

JCSG.org supplies research-grade peptides with documentation available on request, and Reschem publicly lists Semax at R599.00 per vial as a 2026 local benchmark. Domestic courier timeframes for cold-chain peptide shipments within SA typically run 1–3 working days to major centres.

Red flags

Avoid any listing that omits a COA, declines to share HPLC chromatograms, ships ambient without temperature control, or sources from an unverified reshipper. Absence of a stated purity percentage, vague "pharmaceutical grade" labelling without analytical backup, and pricing dramatically below the R599–R900 local band all warrant scrutiny.

Semax Administration Routes Used in Research Models

Intranasal administration is the dominant route in published Semax research, with subcutaneous injection used as a secondary route in rodent neuroprotection models. The intranasal route is thought to facilitate direct CNS access via the olfactory and trigeminal pathways, bypassing first-pass metabolism that would otherwise degrade the heptapeptide rapidly in systemic circulation. Russian clinical literature has historically employed 0.1% and 1% intranasal solutions as the standard delivery format.

Dose ranges reported in rodent literature

In preclinical rodent work, intranasal Semax has typically been administered at 50–100 µg/kg. The Andreeva et al. ischaemia-reperfusion cortex transcriptomic series used comparable microgram-per-kilogram dosing to elicit measurable gene-expression changes in neurotrophin-related pathways. Subcutaneous administration appears in a subset of neuroprotection models where controlled systemic exposure was preferred over mucosal absorption variability. The 2020 ADDF technical report consolidates these methodologies and notes the absence of cross-laboratory dose standardisation.

Researchers designing protocols should recognise that rodent dosing cannot be directly extrapolated to human subjects without pharmacokinetic and safety data that do not currently exist in the published literature.

Scope limits for this research-use page

No standardised human dosing protocol is endorsed here, and SAHPRA has issued no Semax-specific authorisation as of 2026. Researchers designing comparator protocols should review the Selank research peptide profile for an analogous intranasal heptapeptide methodology, and the Epithalon peptide record for contrasting subcutaneous-only administration models.

Related Research Peptides Available in South Africa

Researchers studying neurotrophic signalling and ACTH-fragment pharmacology often run parallel investigations into adjacent peptides available through South African research-chemical suppliers in 2026. The compounds below are the most common comparator and complement molecules in the local catalogue.

Selank is the closest structural analogue to Semax, a synthetic heptapeptide derived from the immunomodulator tuftsin with documented anxiolytic and BDNF-modulating activity in Russian preclinical literature.

Epithalon is a tetrapeptide (Ala-Glu-Asp-Gly) investigated primarily for telomerase activation and pineal-axis effects, offering a contrasting subcutaneous-only administration model for researchers comparing peptide delivery routes.

IGF-1 LR3 is a Long R3 analogue of insulin-like growth factor 1 used in growth-factor signalling research. It is relevant where investigators are mapping crosstalk between IGF and neurotrophin pathways.

NAD+ is studied in metabolic and neuroprotective contexts and is sometimes paired with neuropeptide protocols in mitochondrial-function research designs.

Frequently Asked Questions: Semax Research Peptide SA

Semax is sold in South Africa strictly as an unscheduled research compound, not as a SAHPRA-registered medicine. The questions below address what researchers most commonly raise before purchasing locally in 2026.